Navigation Links
Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Date:6/26/2008

ceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India, with a combined total enrollment of 956 patients.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has the exclusive option to license compounds, which are NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidase inhibitors, as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera retains the right to use the Medidur(TM) delivery system for two of these compounds, and is also exploring other delivery technologies to apply to these compounds.


'/>"/>
SOURCE Alimera Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2010)... NEW YORK, Sept. 3 The QUAD ... houses, presents the New York premiere of the provocative ... (102 minutes), directed and produced by Dr. D. ... Rutledge, a California physician specializing in preventative medicine, chronicles ... DDT in 1972, a ban inspired by the first ...
(Date:9/3/2010)... 3 The Medical Affairs function arguably ... organization, with heavy responsibilities across areas such as ... education. These areas must operate effectively for new ... is one of the challenges facing the Medical ... different roles across the organization. ...
(Date:9/3/2010)... PR Issued on September 1 for the Stock... -- JERUSALEM, September 3, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Breaking Medicine Technology:3 BILLION AND COUNTING Opens in New York at The QUAD Cinema 23 BILLION AND COUNTING Opens in New York at The QUAD Cinema 3Medical Affairs Report Outlines Resource Needs for Group Success 2Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 2Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 3Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 4Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 5Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 6Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend 7Lo Cest Offers a Free Download of a New Bible for the Gay Community 66834 1Lo Cest Offers a Free Download of a New Bible for the Gay Community 66834 2Agility Consulting Partners with pan 28Performance Assessment Network 29 to Bring Custom Private Label Assessment Capability to Human Resource Profes 66829 1Agility Consulting Partners with pan 28Performance Assessment Network 29 to Bring Custom Private Label Assessment Capability to Human Resource Profes 66829 2New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act 66824 1New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act 66824 2New Lumension Webcast Highlights Key Steps to Prepare Healthcare Firms and Business Associates to Comply with New HITECH Act 66824 3
... Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... (FDA) has granted Orphan,Drug Designation for IPLEX(TM) for ... currently conducting a 24-week Phase III,enabling trial for ... grant of,approximately $2.1 million from the Muscular Dystrophy ...
... Calif., Dec. 18 Epeius Biotechnologies,Corporation announced ... Certificate of,Product Registration for Rexin-G(R) from the ... the commercialization of its lead product as ... spectrum of intractable cancers.,Developed as a tumor-targeted ...
Other Medicine Technology:Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 2Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 3ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer 2ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer 3
(Date:9/3/2010)... first clinical trials on a new investigational drug being ... have been successfully completed. , Completion of the initial ... first prepared by researchers at Cardiff University,s Welsh School ... becoming an approved medicine have significantly improved. , ... C, which can lead to liver cancer, cirrhosis and ...
(Date:9/2/2010)... is yet no straightforward way to determine the ... radiation therapies such as stereotactic radiation therapy, used ... high-dose brachytherapy for prostate and other cancers., Radiation ... Center-Arthur G. James Cancer Hospital and Richard J. ... problem by developing a new mathematical model that ...
(Date:9/2/2010)... , , THURSDAY, Sept. 2 (HealthDay News) -- As the ... implemented, many small businesses in the United States will ... a new report shows. During the first phase ... workers will be eligible for these tax credits, according ... "The new law is likely to have a ...
(Date:9/2/2010)... 2 September, 2010 - Elsevier announced today the ... European Menopause and Andropause Society (EMAS) in the ... common management problems in the post-reproductive health of ... the menopause in the context of obesity, epilepsy, ... has summary recommendations as a quick aid for ...
(Date:9/2/2010)... HealthDay Reporter , , WEDNESDAY, Sept. 1 (HealthDay ... stimulating activities have pros and cons when it comes ... with prior research, the study finds that such mental ... normal old age. But folks who loved these ... once symptoms of dementia began to set in, the ...
Breaking Medicine News(10 mins):Health News:First clinical trials successfully completed on potent new hepatitis C drug 2Health News:New model may simplify high-dose radiosurgery planning 2Health News:Health Care Reform Helps Small Businesses Offer Coverage: Report 2Health News:Health Care Reform Helps Small Businesses Offer Coverage: Report 3Health News:Health Care Reform Helps Small Businesses Offer Coverage: Report 4Health News:EMAS publishes position statements about the post-reproductive health of women 2Health News:Mental 'Exercise' May Only Hide Signs of Alzheimer's 2Health News:Mental 'Exercise' May Only Hide Signs of Alzheimer's 3
... 12 The Female Health Company (NYSE Alternext: ... (FDA) Obstetrics and Gynecology Devices Advisory Committee has unanimously voted ... is approvable with a single condition. , ... the product is approvable with the condition that the FC2 ...
... 12 Access MediQuip, LLC, the nation,s ... device management,solutions to the healthcare industry, announced ... national contract for device benefit management services.,The ... Inc. to deliver,implantable device management solutions to ...
... in combination with ribavirin for previously untreated children with ... , KENILWORTH, N.J., Dec. 12 ... announced that the U.S. Food and Drug Administration (FDA) ... REBETOL(R) (ribavirin, USP) combination therapy for use in previously ...
... Dec. 12 Laura Rogers, project director for the ... issued the following statement regarding the U.S. Food and ... off-label usage of certain antibiotics in animal agriculture: , ... antibiotics in animal agriculture helps fuel the increase in ...
... Center in conjunction with Sodexo Health Care Services is pleased ... the original certified kosher hot food vending machine. UH ... state of Ohio, offering patients and their caregivers around the ... , University Hospitals prides itself on the ...
... Insurance,Company (John Hancock) is reinforcing its commitment to ... requirements through an,affiliation with the ClearCert Clearinghouse. ... the year and effective January 1, 2009,will only ... Since beginning ...
Other Medicine News:Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5Health News:Access MediQuip and WellPoint Finalize First National Contract for Implantable Medical Devices 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:Statement From The Pew Charitable Trusts on the U.S. Food and Drug Administration's Reversal on Antibiotics Safeguards in Animal Farming 2Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 2Health News:University Hospitals Case Medical Center Installs First Hot Kosher Vending Machine 3Health News:John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers 2Health News:John Hancock Expands LTC Training Effort with ClearCert High Usage By Producers and Streamlines Process for Insurers 3
Inquire...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
Inquire...
... a compact system featuring,easy setup and flow ... allowing the use of less,expensive disposable tubing ... office or hospital use, the,PSI-TEC III Infiltrator ... - 5" (w) X 8" (l) X ...
Medicine Products: